KSE
Articles
- Page Path
- HOME > Epidemiol Health > Volume 40; 2018 > Article
-
Data Profile
National Epidemiologic Survey of Thyroid cancer (NEST) in Korea -
Chang-Mo Oh1,2
, Hyun-Joo Kong1, Eunyang Kim1, Hyejin Kim1, Kyu-Won Jung1, Sohee Park1,3, Young-Joo Won1 -
Epidemiol Health 2018;40:e2018052.
DOI: https://doi.org/10.4178/epih.e2018052
Published online: October 26, 2018
1Cancer Registration and Statistic Branch, National Cancer Control Institute, National Cancer Center, Goyang, Korea
2Department of Preventive Medicine, Kyung Hee University School of Medicine, Seoul, Korea
3Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Korea
- Correspondence: Young-Joo Won Cancer Registration and Statistic Branch, National Cancer Control Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea E-mail: astra67@ncc.re.kr
• Received: June 27, 2018 • Accepted: October 26, 2018
©2018, Korean Society of Epidemiology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
- The Korea Central Cancer Registry conducted the National Epidemiologic Survey of Thyroid cancer (NEST) to investigate changes in the epidemiological and clinical characteristics of thyroid cancer patients between 1999 and 2008. The NEST was designed to collect representative samples of patients with thyroid cancer diagnosed in the years 1999, 2005, and 2008 using a proportionally stratified and systematic random sampling method. Among 42,891 participants diagnosed with thyroid cancer, 5,796 participants were included in the final study population. This survey collected information on diagnostic methods and date, route of diagnosis, prior medical history and history of thyroid-related disease, tumor, lymph node, metastasis and collaborative stage, and treatment. The NEST dataset was also linked to the cause-of-death database from Statistics Korea. The mean age of the study participants was 46.9 years. The ratio of men to women was 1:5.5. In the analysis of the histologic type of cancer, the proportion of papillary thyroid carcinoma showed an increasing trend (p<0.01). In contrast, the proportion of distant metastasis and the mean tumor size of thyroid cancers showed decreasing trends over time (p<0.01, respectively).
- From 2009 to 2014, thyroid cancer was the most common cancer in South Korea (hereafter Korea). Korea had the highest incidence of thyroid cancer worldwide, according to GLOBOCAN 2012 (Figure 1), and the incidence of thyroid cancer has increased rapidly since 1999 [1,2]. Although the incidence of thyroid cancer has been increasing worldwide, the unprecedented rapid increase of thyroid cancer in Korea is rare in any country. The extremely high incidence of thyroid cancer in Korea is much higher than that of New Caledonia, which was the highest ever previously reported [1,3]. Most previous studies have suggested that the rapid increase in the incidence of thyroid cancer was due to early detection and increased diagnosis; in support of this, the number of cases of micro-sized thyroid cancer has increased [4,5]. Furthermore, although the incidence of thyroid cancer has increased, thyroid cancer mortality has stabilized [6,7]. Therefore, the Korea Central Cancer Registry (KCCR) has collected information on baseline characteristics and factors associated with thyroid cancer through medical chart review. The current epidemiologic study investigated the causes and changes in the clinical characteristics of thyroid cancer and is called the National Epidemiologic Survey of Thyroid cancer (NEST) study.
INTRODUCTION
- The Korea National Cancer Incidence Database
- The NEST data resource was based on the Korea National Cancer Incidence Database (KNCI DB). The KCCR has collected data on nationwide cancer incidence for patients diagnosed since 1999 in Korea and has published cancer statistics since 2004 [8]. In 2002, the KCCR set up the KNCI DB by integrating some regional cancer registries and site-specific data from academic societies with the cancer incidence database of the KCCR [8]. Currently, the KNCI DB includes almost all incident cases of cancer in Korea [1]. In 2014, the coverage of the statistics on cancer incidence in the KNCI DB was estimated to be about 97.8% of the total cancer incidence based on the Ajiki method [1,9]. The microscopic verification percentage of the cancer statistics was approximately 90.0%, and the proportion of death certificates issued was only 1.2% in Korea [10].
DATA RESOURCE
- The National Epidemiologic Survey of Thyroid cancer study
- The KCCR conducted the NEST in 2011 to investigate secular trends in the clinicopathologic features of Korean patients with thyroid cancer. To gather information on the diagnostic characteristics of patients with thyroid cancer, we conducted the NEST through retrospective medical chart review (Figure 2). Thyroid cancer incidence was defined as a newly-appearing topographical code of C73.9 according to the International Classification of Diseases, 10th edition. The questionnaire was developed based on a literature review and evaluated by experts from an academic society (The Korean Thyroid Association, The Korean Endocrine Society, The Korean Society of Pathologists, etc.). A pilot study was conducted to evaluate the feasibility and validity of the questionnaire. The content of the survey was finalized through the pilot study.
- A 2-stage sampling method was used to obtain a nationally representative sample in the NEST study. To select representative patients with thyroid cancer, we obtained data on incident cases of thyroid cancer from the KNCI DB of the KCCR. We selected pools of thyroid cancer patients diagnosed in 1999, 2005, and 2008 from the KNCI DB. The 2005 data were sampled between 1999 and 2008 because thyroid cancer among women became the most frequently diagnosed malignancy in 2005. First, we randomly selected 24 hospitals using proportionate stratification, reflecting the number of patients stratified by regions in each year. Second, we randomly selected cases using proportionate stratification from the 24 hospitals selected in each year. We oversampled cases from 1999 and 2005 because there were insufficient thyroid cancer cases for analysis compared to the year 2008. The sampling proportion was 33% for 1999, 22% for 2005, and 11% for 2008 at the second stage, considering an approximate drop-out rate of 10%.
- Among the 42,891 participants who were diagnosed with thyroid cancer, 6,846 were included in the sampled population using the stratified random sampling method. Of these 6,846 participants, 1,045 cases (15.3%) were excluded because 2 hospitals refused to investigate their medical records, and 5 cases (0.1%) were excluded because of assignment error. Finally, 5,796 participants were included in the analysis (Figure 3). Informed consent was not obtained, but the presented data were anonymized, and the risk of identification was low.
- We collected data regarding age, gender, date of first diagnosis of cancer, date of death, date of the most valid examination for cancer [11], date of surgery, histologic type, the route of detection through which cancer was first detected (screening vs. clinical suspicion), multifocality, extrathyroidal invasion, method of cancer treatment, history of other comorbid diseases, and history of smoking and alcohol drinking. The date of first diagnosis of cancer indicates the date of the first consultation at, or admission to, a hospital for the cancer, the first diagnosis of the cancer by a physician, or the first pathology report and the most valid examination for cancer presents that the date on which the most valid test was performed to confirm the diagnosis of cancer. We also collected data on tumor, lymph node, metastasis (TNM) staging for thyroid cancer according to the sixth edition of the American Joint Committee on Cancer guideline published in 2002 [12].
- The histological types of thyroid cancer were classified according to the International Classification of Diseases for Oncology, third edition (ICD-O-3) as papillary carcinoma (ICD-O-3 codes 8050, 8260, 8340–8344, 8350, and 8450–8460), medullary carcinoma (ICD-O-3 codes 8345 and 8510–8513), follicular carcinoma (ICD-O-3 codes 8290 and 8330–8335), anaplastic carcinoma (ICD-O-3 codes 8020–8035), and others (ICD-O-3 codes 8000–8005, 8337, 8346, and 8347) [13].
- The NEST dataset was linked to the cause-of-death statistics from Statistics Korea (http://kostat.go.kr). Thyroid cancer patients were followed up through December 31, 2016. Five patients were lost to follow-up due to emigration or cancellation of resident registration. The cause-of-death data will be linked to the NEST dataset and updated every year. The research protocol for the present study was approved by the institutional review board of the National Cancer Center (no. NCC2017-0070).
MEASURES
Questionnaire development
Sampling method
Selection of the study participants
Data collection
- Characteristics of study participants by year
- Table 1 shows the baseline characteristics of the study participants according to the diagnosis of thyroid cancer each year. The mean age of thyroid cancer patients in this study was 46.9 years. The ratio of men to women was 1:5.5. According to the histologic type of cancer, the proportion of papillary thyroid carcinoma showed an increasing trend, while the other types of thyroid cancer showed decreasing trends (p for trend <0.01). The proportion of cases of distant metastasis showed a decreasing trend during the study period (p for trend <0.01). The mean tumor size also showed a decreasing trend during the study period (p for trend <0.01). The proportion of patients with lymph node involvement (p for trend <0.01) and distribution of TNM stages differed over time (p for trend <0.01). In particular, the proportion of patients with stage III thyroid cancer increased from 10.9% in 1999 to 22.2% in 2008, while the proportion of those with stage IV thyroid cancer decreased from 11.3% in 1999 to 5.8% in 2008 (p for trend <0.01).
- Number and causes of death among thyroid cancer patients
- We followed thyroid cancer patients until December 31, 2016. During an average of 10.6 years of follow-up, 370 patients died (Table 2). Of these 370 deaths, 128 patients (34.6%) died from primary thyroid cancer, 127 patients (34.3%) died from other types of cancer, and 38 patients (10.3%) died from cardiovascular disease.
- Publications
- Until now, there have only been 2 publications based on the NEST dataset [7,14]. The first is a study of changes in the prevalence of chronic lymphocytic thyroiditis among papillary thyroid cancer patients [14]. Chronic lymphocytic thyroiditis, or Hashimoto thyroiditis, is an autoimmune disease; notably, autoimmune diseases of the thyroid gland are a risk factor for thyroid cancer. Recently, some studies have reported that the incidence of Hashimoto thyroiditis has been increasing, along with thyroid cancer. In the NEST data, the age-standardized prevalence of chronic lymphocytic thyroiditis among thyroid cancer patients increased from 1999 to 2008. This finding suggests that in more recent years, the incidence of thyroid cancer was associated with factors related to autoimmune thyroid diseases or more detailed pathological examination. Another study estimated the difference in age-standardized incidence rates between 1999 and 2008 according to the route of tumor detection (screening detection vs. clinical detection) [7]. These results showed that the increase in the incidence of thyroid cancer in Korea was mainly due to over-detection resulting from the widespread utilization of sensitive imaging tools such as ultrasonography.
DATA RESOURCE USE
- The strength of the NEST cohort is that first, it represents the entirety of patients with thyroid cancer in Korea. Second, it also includes multiple variables, such as tumor size (mm), information on tumor stage, and method of treatment, that are not in the KCCR database. Various conversions are possible, because the information about tumor stage was collected using a collaborative stage data collection system (https://cancerstaging.org/cstage/). Third, it is possible to analyze patients’ prognosis and prognostic factors, because the NEST dataset has been linked to death data collected by Statistics Korea. The additional linkage allows researchers to conduct more specific analyses of relevant variables to obtain valuable results. This linked dataset has been used to analyze survival outcomes for thyroid cancer patients after diagnosis or according to certain variables, with some seeking to identify patient characteristics associated with specific outcomes.
- There are some limitations to this study. First, our data may have been affected by misclassification bias regarding the route of detection. We reviewed medical records retrospectively. Although it was assumed that medical charts were unbiased records of patients’ information, there may be discrepancies between patients’ actual information and the medical information recorded on the chart. Indeed, Fouwels et al. [15] found that unhealthy lifestyle habits recorded in medical charts were underreported compared to the lifestyle habits that participants reported in their lifestyle questionnaire survey. Second, there were many missing variables, such as smoking history (missing, 12.5-45.2%), alcohol drinking (missing, 12.0-59.1%), or method of detection (missing, 13.1%). This missing information may result in bias. Third, some thyroid cancer cases were excluded due to refusal of the hospital to investigate or assignment error. However, we were able to re-calculate the number of non-responders for each stratum, because we knew the total number of incident cancer cases for each stratum. Therefore, we used post-stratification weights, and the effects of bias due to non-response units are expected to be minimal. Fourth, the NEST does not contain any information concerning the socioeconomic status, comorbidities, radiation exposure, or body mass index of participants, which are major risk or prognostic factors for thyroid cancer.
- Despite these limitations, we expect the annual number of publications using the NEST dataset to increase. Publishable studies using the NEST dataset can cover a diverse range of topics. Potential researchers can examine the changes in characteristics associated with thyroid cancer by year, longitudinal patterns of treatment, and survival by prognostic factors. Regional comparisons have included evaluations of the impact of clinical evidence or guidelines, as well as health care policies.
STRENGTHS AND WEAKNESSES
- The KCCR developed the website for the NEST data (available from: http://kccrsurvey.cancer.go.kr/index.do). The NEST data are freely available. To download the NEST data, registration is required to access the website. After logging into the website, users click to request the NEST data, after which they have to sign a consent form, select the data, and write a brief research proposal. After approval by the staff, users can download the required data.
DATA ACCESSIBILITY
ACKNOWLEDGEMENTS
Figure 1.International comparisons of incidence rates of thyroid cancer. OECD, Organization for Economic Cooperation and Development. Adapted from: [1] The standard population per 100,000 people was calculated using Segi’s world standard population; [2] The estimated incidence rate in 2012 based on the data from GLOBOCAN 2012, International Agency for Research on Cancer, 2013; and [3] The observed incidence rate in year 2012 was obtained from the Korea Central Cancer Registry.
Table 1.Baseline characteristics of study participants with thyroid cancer by year
| Variables | Total |
Year |
p for trend1 | ||
|---|---|---|---|---|---|
| 1999 | 2005 | 2008 | |||
| Total (n) | 5,796 | 891 | 2,355 | 2,550 | |
| Age (yr) | 46.9±12.4 | 46.0±14.3 | 47.3±12.5 | 46.8±11.6 | 0.64 |
| Tumor size (mm) | 13.3±11.7 | 21.5±15.9 | 13.6±11.1 | 10.5±9.0 | <0.01 |
| Gender | 0.13 | ||||
| Men | 898 (15.5) | 136 (15.3) | 328 (13.9) | 434 (17.0) | |
| Women | 4,898 (84.5) | 755 (84.7) | 2,027 (86.1) | 2,116 (83.0) | |
| Histologic type (carcinoma) | <0.01 | ||||
| Follicular | 173 (3.0) | 62 (7.0) | 66 (2.8) | 45 (1.8) | |
| Papillary | 5,500 (94.9) | 779 (87.4) | 2,243 (95.2) | 2,478 (97.2) | |
| Medullary | 43 (0.7) | 13 (1.4) | 19 (0.8) | 11 (0.4) | |
| Anaplastic | 26 (0.5) | 15 (1.7) | 6 (0.3) | 5 (0.2) | |
| Others | 54 (0.9) | 22 (2.5) | 21 (0.9) | 11 (0.4) | |
| Regional lymph node involvement | <0.01 | ||||
| No | 2,466 (42.6) | 268 (30.1) | 1,012 (43.0) | 1,186 (46.5) | |
| Yes | 2,047 (35.3) | 319 (35.8) | 799 (33.9) | 929 (36.4) | |
| Unknown | 1,283 (22.1) | 304 (34.1) | 544 (23.1) | 435 (17.1) | |
| Distant metastasis | <0.01 | ||||
| No | 5,380 (92.8) | 774 (86.9) | 2,196 (93.3) | 2,410 (94.5) | |
| Yes | 34 (0.6) | 15 (1.7) | 14 (0.6) | 5 (0.2) | |
| Unknown | 382 (6.6) | 102 (11.4) | 145 (6.1) | 135 (5.3) | |
| AJCC sixth edition stage | <0.01 | ||||
| I | 3,038 (52.4) | 428 (48.0) | 1,249 (53.0) | 1,361 (53.3) | |
| II | 49 (0.9) | 14 (1.6) | 23 (1.0) | 12 (0.5) | |
| III | 1,036 (17.9) | 97 (10.9) | 373 (15.8) | 566 (22.2) | |
| IV | 426 (7.3) | 101 (11.3) | 178 (7.6) | 147 (5.8) | |
| Unknown | 1,247 (21.5) | 251 (28.2) | 532 (22.6) | 464 (18.2) | |
Table 2.Number and causes of death among thyroid cancer patients
| Characteristics | Thyroid cancer patients1 |
|---|---|
| Total (n) | 5,796 |
| Men | 898 (15.5) |
| Women | 4,898 (84.5) |
| Follow-up period (mean±SD, yr) | 10.6±3.3 |
| Censored cases | 5 (0.1) |
| No. of deaths (n=370) | 370 (6.4) |
| Men | 109 (29.5) |
| Women | 261 (70.5) |
| Causes of death (ICD-10 code) | |
| Thyroid cancer (C73) | 128 (34.6) |
| Other types of cancer (C00 – C97, except C73) | 127 (34.3) |
| Cardiovascular disease (I00 – I99) | 38 (10.3) |
| Other causes of death | 77 (20.8) |
- 1. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat 2017;49:292-305.ArticlePubMedPMCPDF
- 2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.ArticlePubMed
- 3. Truong T, Rougier Y, Dubourdieu D, Guihenneuc-Jouyaux C, Orsi L, Hémon D, et al. Time trends and geographic variations for thyroid cancer in New Caledonia, a very high incidence area (1985-1999). Eur J Cancer Prev 2007;16:62-70.ArticlePubMed
- 4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-2167.Article
- 5. Cho BY, Choi HS, Park YJ, Lim JA, Ahn HY, Lee EK, et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 2013;23:797-804.ArticlePubMedPMC
- 6. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317-322.ArticlePubMed
- 7. Park S, Oh CM, Cho H, Lee JY, Jung KW, Jun JK, et al. Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study. BMJ 2016;355:i5745.ArticlePubMedPMC
- 8. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat 2005;37:325-331.ArticlePubMedPMCPDF
- 9. Ajiki W, Tsukuma H, Oshima A. Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index. Nihon Koshu Eisei Zasshi 1998;45:1011-1017 (Japanese).PubMed
- 10. Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2014. Goyang: Korea Central Cancer Registry; 2016. p 11 (Korean).
- 11. MacLennan R. Items of patient information which may be collected by registries. In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, editors. Cancer registration: principles and methods. Lyon: International Agency for Research on Canser; 1991. p 54-55.
- 12. Greene FL, Page DL, Fleming ID, Fritz AO, Balch CM, Haller DG, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. p 77-88.
- 13. Egevad L, Heanue M, Berney D, Fleming K, Ferlay J. Histological groups. In: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al, eds. Cancer incidence in five continents, volume IX. Lyon: International Agency for Research on Cancer; 2007. p 61-66.
- 14. Oh CM, Park S, Lee JY, Won YJ, Shin A, Kong HJ, et al. Increased prevalence of chronic lymphocytic thyroiditis in Korean patients with papillary thyroid cancer. PLoS One 2014;9:e99054.ArticlePubMedPMC
- 15. Fouwels AJ, Bredie SJ, Wollersheim H, Schippers GM. A retrospective cohort study on lifestyle habits of cardiovascular patients: how informative are medical records? BMC Health Serv Res 2009;9:59.ArticlePubMedPMCPDF
REFERENCES
Figure & Data
References
Citations
Citations to this article as recorded by 
- A novel electrochemical biosensor based on dual signal amplification of CMK-3@AuNPs and ATRP for DR1 detection
Fuchun Si, Xiaojing Cui, Yaping Zhang, Yifan Li, Huaixia Yang, Yanju Liu
Sensors and Actuators B: Chemical.2024; 403: 135080. CrossRef - Hashimoto Thyroiditis and Mortality in Patients with Differentiated Thyroid Cancer: The National Epidemiologic Survey of Thyroid Cancer in Korea and Meta-Analysis
Injung Yang, Jae Myung Yu, Hye Soo Chung, Yoon Jung Kim, Yong Kyun Roh, Min Kyu Choi, Sung-ho Park, Young Joo Park, Shinje Moon
Endocrinology and Metabolism.2024; 39(1): 140. CrossRef - Cost-Utility Analysis of Early Detection with Ultrasonography of Differentiated Thyroid Cancer: A Retrospective Study on a Korean Population
Han-Sang Baek, Jeonghoon Ha, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Sungju Kim, Dong-Jun Lim, Chul-Min Kim
Endocrinology and Metabolism.2024; 39(2): 310. CrossRef - Incidence of thyroid cancer in Abu Dhabi, UAE: A registry-based study
Eiman Alseddeeqi, Ajda Altinoz, Abderrahim Oulhaj, Abubaker Suliman, LuaiA Ahmed
Journal of Cancer Research and Therapeutics.2023; 19(2): 321. CrossRef - A Case of Cowden Syndrome Presenting with Diverse Cutaneous Manifestations
Jongeun Lee, Dong Min Shin, Se Jin Oh, Ji-Hye Park, Dongyoun Lee
Annals of Dermatology.2023; 35(2): 146. CrossRef - Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park
Endocrinology and Metabolism.2023; 38(1): 93. CrossRef - Survival Comparison of Incidentally Found versus Clinically Detected Thyroid Cancers: An Analysis of a Nationwide Cohort Study
Shinje Moon, Eun Kyung Lee, Hoonsung Choi, Sue K. Park, Young Joo Park
Endocrinology and Metabolism.2023; 38(1): 81. CrossRef - Quantification and Pattern of Central Compartment Lymph Nodes in pN1a Papillary Thyroid Cancer Patients
Chang Liu, Hui Liu, Cong Bian, Xi-Yu Yao, Yu Wu, Shun-Jin Chen
Ear, Nose & Throat Journal.2022; : 014556132211044. CrossRef - Dyslipidemia Risk in Thyroid Cancer Patients: A Nationwide Population-Based Cohort Study
Youhyun Song, Hye Sun Lee, Goeun Park, Sang-Wook Kang, Ji Won Lee
Frontiers in Endocrinology.2022;[Epub] CrossRef - Clinical Significance of Tumor Size in Gross Extrathyroidal Extension to Strap Muscles (T3b) in Papillary Thyroid Carcinoma: Comparison with T2
Joonseon Park, Il Ku Kang, Ja Seong Bae, Jeong Soo Kim, Kwangsoon Kim
Cancers.2022; 14(19): 4615. CrossRef - TERT Promoter Mutations and the 8th Edition TNM Classification in Predicting the Survival of Thyroid Cancer Patients
Jun Park, Sungjoo Lee, Kyunga Kim, Hyunju Park, Chang-Seok Ki, Young Lyun Oh, Jung Hee Shin, Jee Soo Kim, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim
Cancers.2021; 13(4): 648. CrossRef - Adequacy and Effectiveness of Watson For Oncology in the Treatment of Thyroid Carcinoma
Hyeok Jun Yun, Hee Jun Kim, Soo Young Kim, Yong Sang Lee, Chi Young Lim, Hang-Seok Chang, Cheong Soo Park
Frontiers in Endocrinology.2021;[Epub] CrossRef - Clinicopathological features of Differentiated Thyroid Cancer presenting in the UK versus internationally: An observational cohort study
R. Sawant, S.Y. Hey, K. Hulse, A. Hay, F.W. Gibb, R. Adamson, I.J. Nixon
Clinical Otolaryngology.2021; 46(3): 522. CrossRef - Analyses of the Association between Thyroid Cancer and Osteoporosis/Fracture Histories: A Cross-Sectional Study Using KoGES HEXA Data
Young-Ju Jin, Chang-Myeon Song, Bum-Jung Park, Hyo-Geun Choi
International Journal of Environmental Research and Public Health.2021; 18(9): 4732. CrossRef - Clinicopathological Features of Patients Diagnosed with Both Primary Thyroid Cancer and Primary Renal Cell Cancer and Its Comparison with Patients with Thyroid Cancer or Renal Cell Cancer Alone
Jun Park, Young Nam Kim, Hyunsoo Ryoo, Hyunju Park, So Young Park, Tae Hyuk Kim, Jae Hoon Chung, Seong Il Seo, Sun Wook Kim
International Journal of Thyroidology.2021; 14(1): 28. CrossRef - Proposal of a New Prognostic Model for Differentiated Thyroid Cancer with TERT Promoter Mutations
Jun Park, Sungjoo Lee, Jiyun Park, Hyunju Park, Chang-Seok Ki, Young-Lyun Oh, Jung-Hee Shin, Jee-Soo Kim, Sun-Wook Kim, Jae-Hoon Chung, Kyunga Kim, Tae-Hyuk Kim
Cancers.2021; 13(12): 2943. CrossRef - Thyroid cancer awareness among women in the asir region of Saudi Arabia
MajedSaad Al Fayi
King Khalid University Journal of Health Sciences.2021; 6(1): 27. CrossRef - Spatial distribution and determinants of thyroid cancer incidence from 1999 to 2013 in Korea
Jieun Jang, Dae-Sung Yoo, Byung Chul Chun
Scientific Reports.2021;[Epub] CrossRef - Association of Screening by Thyroid Ultrasonography with Mortality in Thyroid Cancer: A Case–Control Study Using Data from Two National Surveys
Jae Kwan Jun, Soon-Young Hwang, Seri Hong, Mina Suh, Kui Son Choi, Kyu-Won Jung
Thyroid.2020; 30(3): 396. CrossRef - Thyroid cancer among patients with thyroid nodules in Yemen: a three-year retrospective study in a tertiary center and a specialty clinic
Butheinah A. Al-Sharafi, Jamila A. AlSanabani, Ibraheem M. Alboany, Amani M. Shamsher
Thyroid Research.2020;[Epub] CrossRef Emerging Roles of Long Noncoding RNA Regulator of Reprogramming in Cancer Treatment
Di-Er Sun, Shu-Yuan Ye
Cancer Management and Research.2020; Volume 12: 6103. CrossRef- Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea
Jee Hee Yoon, Min Ji Jeon, Mijin Kim, A. Ram Hong, Hee Kyung Kim, Dong Yeob Shin, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Ho-Cheol Kang, Domenico Albano
PLOS ONE.2020; 15(8): e0238207. CrossRef - Association between Family Histories of Thyroid Cancer and Thyroid Cancer Incidence: A Cross-Sectional Study Using the Korean Genome and Epidemiology Study Data
Soo-Hwan Byun, Chanyang Min, Hyo-Geun Choi, Seok-Jin Hong
Genes.2020; 11(9): 1039. CrossRef - Circular RNAs Regulate Cancer Onset and Progression via Wnt/β-Catenin Signaling Pathway
Yun-Feng Li, Jian Zhang, Lei Yu
Yonsei Medical Journal.2019; 60(12): 1117. CrossRef
PubReader
ePub Link
Cite
XML DownloadNational Epidemiologic Survey of Thyroid cancer (NEST) in Korea
Figure 1. International comparisons of incidence rates of thyroid cancer. OECD, Organization for Economic Cooperation and Development. Adapted from: [1] The standard population per 100,000 people was calculated using Segi’s world standard population; [2] The estimated incidence rate in 2012 based on the data from GLOBOCAN 2012, International Agency for Research on Cancer, 2013; and [3] The observed incidence rate in year 2012 was obtained from the Korea Central Cancer Registry.
Figure 2. Summary of the National Epidemiologic Survey of Thyroid cancer study procedure.
Figure 3. Flow chart for study participant selection.
Figure 1.
Figure 2.
Figure 3.
National Epidemiologic Survey of Thyroid cancer (NEST) in Korea
| Variables | Total | Year |
p for trend |
||
|---|---|---|---|---|---|
| 1999 | 2005 | 2008 | |||
| Total (n) | 5,796 | 891 | 2,355 | 2,550 | |
| Age (yr) | 46.9±12.4 | 46.0±14.3 | 47.3±12.5 | 46.8±11.6 | 0.64 |
| Tumor size (mm) | 13.3±11.7 | 21.5±15.9 | 13.6±11.1 | 10.5±9.0 | <0.01 |
| Gender | 0.13 | ||||
| Men | 898 (15.5) | 136 (15.3) | 328 (13.9) | 434 (17.0) | |
| Women | 4,898 (84.5) | 755 (84.7) | 2,027 (86.1) | 2,116 (83.0) | |
| Histologic type (carcinoma) | <0.01 | ||||
| Follicular | 173 (3.0) | 62 (7.0) | 66 (2.8) | 45 (1.8) | |
| Papillary | 5,500 (94.9) | 779 (87.4) | 2,243 (95.2) | 2,478 (97.2) | |
| Medullary | 43 (0.7) | 13 (1.4) | 19 (0.8) | 11 (0.4) | |
| Anaplastic | 26 (0.5) | 15 (1.7) | 6 (0.3) | 5 (0.2) | |
| Others | 54 (0.9) | 22 (2.5) | 21 (0.9) | 11 (0.4) | |
| Regional lymph node involvement | <0.01 | ||||
| No | 2,466 (42.6) | 268 (30.1) | 1,012 (43.0) | 1,186 (46.5) | |
| Yes | 2,047 (35.3) | 319 (35.8) | 799 (33.9) | 929 (36.4) | |
| Unknown | 1,283 (22.1) | 304 (34.1) | 544 (23.1) | 435 (17.1) | |
| Distant metastasis | <0.01 | ||||
| No | 5,380 (92.8) | 774 (86.9) | 2,196 (93.3) | 2,410 (94.5) | |
| Yes | 34 (0.6) | 15 (1.7) | 14 (0.6) | 5 (0.2) | |
| Unknown | 382 (6.6) | 102 (11.4) | 145 (6.1) | 135 (5.3) | |
| AJCC sixth edition stage | <0.01 | ||||
| I | 3,038 (52.4) | 428 (48.0) | 1,249 (53.0) | 1,361 (53.3) | |
| II | 49 (0.9) | 14 (1.6) | 23 (1.0) | 12 (0.5) | |
| III | 1,036 (17.9) | 97 (10.9) | 373 (15.8) | 566 (22.2) | |
| IV | 426 (7.3) | 101 (11.3) | 178 (7.6) | 147 (5.8) | |
| Unknown | 1,247 (21.5) | 251 (28.2) | 532 (22.6) | 464 (18.2) | |
| Characteristics | Thyroid cancer patients |
|---|---|
| Total (n) | 5,796 |
| Men | 898 (15.5) |
| Women | 4,898 (84.5) |
| Follow-up period (mean±SD, yr) | 10.6±3.3 |
| Censored cases | 5 (0.1) |
| No. of deaths (n=370) | 370 (6.4) |
| Men | 109 (29.5) |
| Women | 261 (70.5) |
| Causes of death (ICD-10 code) | |
| Thyroid cancer (C73) | 128 (34.6) |
| Other types of cancer (C00 – C97, except C73) | 127 (34.3) |
| Cardiovascular disease (I00 – I99) | 38 (10.3) |
| Other causes of death | 77 (20.8) |
Table 1. Baseline characteristics of study participants with thyroid cancer by year
Values are presented as mean±standard deviation or number (%). AJCC, American Joint Committee on Cancer. p for trends were tested by simple linear regression model for continuous variables and by the Mantel-Haenzel chi-square test for categorical variables.
Table 2. Number and causes of death among thyroid cancer patients
Values are presented as number (%). SD, standard deviation; ICD-10, International Classification of Diseases, 10th edition. Thyroid cancer patients were followed up through December 31, 2016.
